drugset
drugset / Trial / NCT02265666

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

NCT02265666 ↗

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS Tablet FF in comparison to the tablet C at a dose of 5 mg after a standard breakfast in healthy male volunteers

Timeline

Start
2001-10
Primary completion
2001-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 5 mg —

Indications

No indication recorded.